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Depression is a multicausal disorder and has been associated with metabolism regulation
and immuno-inflammatory reaction. The anorectic molecule nesfatin-1 has recently been
characterized as a potential mood regulator, but its precise effect on depression and
the possible mechanisms remain unknown, especially when given peripherally. In the
present study, nesfatin-1 was intraperitoneally injected to the rats and the depression-like
behavior and activity of the hypothalamic-pituitary-adrenal (HPA) axis were evaluated. The
plasma concentrations of nesfatin-1, interleukin 6 (IL-6), and C-reactive protein (CRP);
and the hypothalamic expression levels of nesfatin-1, synapsin I, and synaptotagmin
I mRNA were evaluated in nesfatin-1 chronically treated rats. The results showed
that both acute and chronic administration of nesfatin-1 increased immobility in the
forced swimming test (FST), and resulted in the hyperactivity of HPA axis, as indicated
by the increase of plasma corticosterone concentration and hypothalamic expression
of corticotropin-releasing hormone (CRH) mRNA. Moreover, after chronic nesfatin-1
administration, the rats exhibited decreased activity and exploratory behavior in the open
field test (OFT) and increased mRNA expression of synapsin I and synaptotagmin I in
the hypothalamus. Furthermore, chronic administration of nesfatin-1 elevated plasma
concentrations of IL-6 and CRP, which were positively correlated with despair behavior,
plasma corticosterone level, and the hypothalamic mRNA expression of synapsin I and
synaptotagmin I. These results indicated that exogenous nesfatin-1 could induce the
immune-inflammatory activation, which might be a central hug linking the depression-like
behavior and the imbalanced mRNA expression of synaptic vesicle proteins in the
hypothalamus.
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INTRODUCTION
As a metabolic disorder, depression has been associated with
anorexigenic or orexigenic peptides (Lang and Borgwardt, 2013;
Bali et al., 2014). Nesfatin-1 is a newly discovered anorexigenic
factors that cleaved from its precursor nucleobindin 2 (NUCB2;
Oh et al., 2006; Stengel et al., 2009). Based on the findings
that nesfatin-1 is distributed in the stress-related brain regions,
including the hypothalamus (Oh et al., 2006; Brailoiu et al.,
2007; Price et al., 2008) and co-localized with stress-related
substances (Oh et al., 2006; Kohno et al., 2008; Goebel-Stengel
and Wang, 2013), attention has been focused on finding a
possible link between nesfatin-1 and depression (Yoshida et al.,
2010; Emmerzaal and Kozicz, 2013). It has been reported that
the plasma nesfatin-1 level is statistically higher in patients
with major depressive disorder (Ari et al., 2011) and associated
with the elevated scores of anxiety and depression (Ari et al.,
2011; Hofmann et al., 2013), and intracerebroventricular (ICV)
injection of nesfatin-1 could induce anxiety- and fear-related
behaviors (Merali et al., 2008). Results of our previous study
showed that acute stress could increase the plasma concentration
and hypothalamic mRNA expression of NUCB2/nesfatin-1 in
rats (Xu et al., 2015). However, the causality between nesfatin-
1 and anxiety or depression-like changes remains unknown, and
little is known about the effect of nesfatin-1 on the neuropsychic
behaviors when given peripherally.
Although a specific nesfatin-1 receptor has yet to be identified
and thus the actual site of action of this peptide has not
yet been determined, compelling evidences, especially the fact
that co-localization of nesfatin-1 with corticotropin-releasing
hormone (CRH) in the paraventricular nucleus (PVN; Foo et al.,
2008), suggest that the physiological effects of nesfatin-1 are
associated with the hypothalamic-pituitary-adrenal (HPA) axis.
It has also been reported that ICV administration of nesfatin-1
could elevate the plasma levels of adrenocorticotrop hormone
(ACTH) and corticosterone (CORT) in rats (Konczol et al.,
2010; Yoshida et al., 2010), the mechanism of which might be
mediated by its effect on hypothalamic CRH neurons (Yoshida
et al., 2010). However, there is no report about the effect of
peripherally administered nesfatin-1 on the HPA axis, which
has long been taken as one important factor that triggers the
depressive episodes.
Synaptotagmin and synapsin are major component proteins
of the synaptic vesicle membrane and are required for vesicle
fusion and neurotransmitter release (Thome et al., 2001). Our
previous study demonstrated that the mRNA expressions levels
of synaptotagmin I and synapsin I were both increased in
the hypothalami of chronically stressed rats (Ge et al., 2013).
Consistent with these findings, stress-induced changes in these
two proteins in the hippocampus or cortex after chronic stress
have also been observed in other studies (Thome et al., 2001;
Wu et al., 2007). Moreover, it has also been reported that
antidepressant treatment can alleviate depressive symptoms by
inhibiting their expression (Wu et al., 2007; Dagyte et al., 2011;
Müller et al., 2011). Given the effect of synaptic vesicle proteins
on the pathogenesis of depression and their interaction with
anorexigenic or orexigenic neurotransmitters (Fried et al., 1995;
Papke et al., 2012; Poretti et al., 2015), one of the aims of the
present study is to investigate the potential effect of nesfatin-1
on the expression of synaptotagmin I and synapsin I in the
hypothalamus.
Depression as an inflammatory disorder is mediated by
pro-inflammatory cytokines (Lang and Borgwardt, 2013; Maes
et al., 2014). Meta-analyses have indicated that the most
robust evidence-based inflammatory markers associated with
depression include interleukin-6 (IL-6), C-reactive protein
(CRP), and TNF-a (Dowlati et al., 2010). An increasing number
of studies have demonstrated that elevated levels of plasma
IL-6 and CRP levels are associated with an increased risk of
depression (Liu et al., 2014; Wium-Andersen et al., 2014), and
can even predict subsequent depressive symptoms (Valkanova
et al., 2013), although no significant correlation between IL-6 or
CRP and depression has also been reported (Chocano-Bedoya
et al., 2014). Considering the changes of the production of
pro-inflammatory cytokines and neuropeptides associated with
energy and metabolism regulation in depression (Martinez et al.,
2012; Wang et al., 2015), another objective of this study is
to investigate whether the immune-inflammatory response is
a factor involved in the association between nesfatin-1 and
depression.
To gain further insights into the association between
nesfatin-1 and depression, nesfatin-1 was administered to rats
with a single dose or chronically in the present study, and the
depression-like behavior and activity of the HPA axis were
evaluated. Additionally, the plasma nesfatin-1concentration
and the hypothalamic expression of NUCB2/nesfatin-1
mRNA were examined in nesfatin-1 chronically treated
rats. Moreover, the plasma concentrations of CRP and IL-6 and
the mRNA expression of synapsin I and synaptotagmin I in
the hypothalamus were also evaluated in nesfatin-1 chronically
treated rats.
EXPERIMENTAL PROCEDURES
Animals and Drugs
Male Sprague-Dawley (SD) rats, 2 months of age, were purchased
from Anhui Experimental Animal Center of China. The rats
were maintained under a 12:12 h light: dark cycle (lights on at
07:00 h), housed 3-4 per cage (43 cm length× 31 cm width ×
19 cm height) with access to food and water ad libitum. The
ambient temperature was maintained at 21–22◦C with 50–60%
relative humidity. All the experimental procedures in this study
were approved by the Animal Care and Use Committee at Anhui
Medical University, which complies with the National Institute of
Health Guide for the Care and Use of Laboratory Animals (NIH
publication No. 85-23, revised 1985).
Nesfatin-1 purchased from Phoenix Pharmaceuticals, Inc.
(Burlingame, CA, USA) was dissolved in sterile saline solution
(0.9% w/v sodium chloride) and administered to the rats by
intraperitoneal (i.p.) injection.
Experiment 1: Single-dose Administration
of Nesfatin-1
Twenty-four SD rats were randomly divided into four groups
including control and nesfatin-1(10, 20, 40µg/kg) groups.
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Approximately 30min after the i.p. injection of sterile saline
solution or nesfatin-1 at the corresponding dose, a 5-min FST
was conducted by placing each rat in a cylinder (height: 60 cm;
diameter: 25 cm) containing water at 22 ± 2◦C and a depth of
30 cm. The rats were anesthetized and decapitated immediately
after the FST.
Experiment 2: Chronic Administration of
Nesfatin-1
Forty SD rats were divided into 4 groups matching based on
the bodyweight and the result of the first open field test (OFT).
The groups included a control and nesfatin-1(10, 20, 40µg/kg)
groups. All the rats received a daily injection of sterile saline
solution or nesfatin-1 at the corresponding dose. The animals
were continuously treated between 0800 and 1000 h for 3 weeks
before the behavioral test. Figure 1 shows the scheme of chronic
administration of nesfatin-1.
Behavioral Tests
Behavioral tests were performed in a soundproof room with a
neutral environment. All of the tests were conducted between
0830 and 1430, with matching between the groups. The observers
were blind to the treatment. The behavioral tests were monitored
and recorded by a digital camera interfaced with a computer
running the ANY-maze video imaging software (Stoelting Co,
Wood Dale, USA).
Open-field Test
The open-field test was conducted before and on day 10 and
20 of the treatment period. The apparatus consisted of a black
square arena 100 × 100 cm, with a black wall 30 cm high. The
floor was marked with a grid that divided the floor into 16 equal-
sized squares. During a 5-min observation period, the rats in
experiment 2 were placed at one corner of the apparatus facing
the wall. Total moving distance, duration in the center, and the
frequencies of rearing and grooming were recorded.
Sucrose Preference Test
A sucrose preference test was also carried out before, during, and
after nesfatin-1 administration. After a 12-h period of food and
water deprivation, all the animals in experiment 2 were given free
access to two bottles containing plain water and a 2% sucrose
solution, respectively. 6 h later, the volumes of water and sucrose
consumed were measured. The percentage of sucrose solution
compared with the total liquid ingested was used as a measure
of the rats’ sensitivity to reward.
Forced Swimming Test citation(FST)
The FST was carried conducted according to the method
described in our previous study (Ge et al., 2013). The behavioral
cylinder was 60 cm high, 25 cm in diameter, filled with 30 cm of
water and maintained at 22 ± 2 ◦C. The FST paradigm included
2 phases: an initial 15min pre-test followed by a 5min test 24 h
later. Rats were considered to be immobile when they did not
make any active movements. Struggling was considered to be the
rats making active movements with their forepaws in and out of
the water along the side of the swim chamber. Swimming was
considered to be the rats making active swimming or circular
movements.
Measurement of the Plasma
Concentrations of CORT, Nesfatin-1, IL-6,
and CRP
Immediately after the FST in experiment 1 or 24 h after the last
behavioral test in experiment 2, the rats were deeply anesthetized
with chloral hydrate and the blood was taken from the abdominal
aorta. The plasma was collected and the concentrations of CORT,
nesfatin-1, IL-6, and CRP were measured using commercially
available Enzyme-Linked Immunosorbent Assay (ELISA) kits
(CORT: Enzo Life Sciences, Inc., USA; nesfatin-1: Cusabio
Biotech. Co., LTD, Wuhan, Hubei, China; CRP and IL-6:
FIGURE 1 | Scheme of experiment 2. Annotations: OFT, open-field test; SPT, sucrose preference test; FST, forced swimming test; CORT, corticosterone; IL-6,
interleukin-6; CRP, C-reactive protein; BG, Blood glucose; INS, insulin; TC, total cholesterol; TG, triglycerides; FFA, free fatty acid; LDL, low density lipoprotein; VLDL,
very low density lipoprotein; HDL, high density lipoprotein.
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Yuanye Biotech. Co., LTD, Shanghai, China) according to the
manufacturer’s instruction.
RNA Isolation and Real Time PCR
After blood collection, five rats in each group were selected
randomly to collect the hypothalamus and hippocampus to test
the parameters selected for the present study, and the samples of
the other rats in experiment 2 were used to evaluate the other
parameters. The hypothalami were rapidly dissected and frozen
quickly in liquid nitrogen, and stored at -80◦C. Total RNA was
extracted using the TRIzol (Invitrogen, Carlsbad, CA) method.
cDNA was synthesized using reverse transcriptase (Promega,
Wisconsin, USA). Q-PCR was performed using the SYBR Green
PCR Kit (Applied Biosystems, USA) and an ABI Prism 7000
Sequence Detector system in a 25µL volume for 40 cycles (15 s
at 95◦C; 60 s at 62◦C for rat β-actin, CRH, NUCB2/nesfatin-
1, synaptotagmin I, and synapsin I). The primers used in
our study were as follows: rat β-actin 5′-TTGCTGACAGGA
TGCAGAA-3′ and 5′-ACCAATCCACACAGAGTACTT-3′; rat
CRH 5′-CAGAACAACAGTGCGGGCTCA-3′ and 5′-AAGGCA
GACAGGGCGACAGAG-3′; rat NUCB2 /nesfatin-1 5′- CAA
GGGAAAAATCTGGGCCG -3′ and 5′- ACAGTACCGTGC
TTGGATGG -3′; rat synaptotagmin I 5′-CTTGAGCAACCA
ACATCCGC-3′ and 5′-ATGACTGGCACTCACCATTTTT-3′;
rat synapsin I 5′-GTTCTTCGGAATGGGGTCAAA-3′ and 5′-
GAACCATCTGGGCAAACACC-3′. The relative amount of the
target gene was calculated using the 2−11Ct method, and the
result from each sample was normalized against that of the
β-actin.
Statistical Analysis
All statistical analyses were performed using SPSS (Statistical
Package for the Social Sciences) version 12.0.1 (SPSS Inc.,
Chicago, IL, USA). Data are expressed as the mean ± S.E.M.,
and P < 0.05 was considered statistically significant. Between-
group effects on body weight and the performance in the OFT
and sucrose preference were analyzed using a Two-way repeated-
measure ANOVAwith group as between factor and day as within
factor followed by a least significant difference (LSD). Statistical
analyses of between-group effects on behavioral performance,
plasma concentrations of CORT, nesfatin-1, IL-6, and CBP, and
the hypothalamic mRNA expression of CRH, NUCB2/nesfatin-1,
synaptotagmin I, and synapsin I were conducted using ANOVA
followed by LSD post hoc tests. A correlation analysis was
performed using the Pearson correlation test or the Spearman
correlation test when necessary.
RESULTS
Increased Immobility in the FST and
Hyperactivity of the HPA Axis Induced by a
Single Dose of Nesfatin-1
As shown in Figure 2A, a single dose of nesfatin-1 (20, 40µg/kg)
significantly increased the immobility of rats in the FST (F =
2.369, P = 0.109); nesfatin-1 (10, 20, 40µg/kg) also decreased
the swimming time (F = 4.606, P = 0.017). Consistent with
FIGURE 2 | Effect of a single dose of nesfatin-1 on the immobility in the
FST, the HPA axis, and the hypothalamic mRNA expression of
nesfatin-1 in rats. The data are presented as the mean ± SEM, with n = 6
for each group. The immobile time was increased and the swimming time was
decreased in the nesfatin-1-treated rats compared with the controls (A). The
nesfatin-1-treated rats exhibited hyperactivity of the HPA axis, as indicated by
the elevated serum CORT concentration (B) and CRH mRNA expression in the
hypothalamus (B). The mRNA expression of nesfatin-1 in the hypothalamus
was not significantly different between the nesfatin-1-treated rats and the
controls (C). *P < 0.05 and **P < 0.001 compared with the control group.
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this result, the plasma CORT concentration was increased in
the rats administered a single dose of nesfatin-1 (Figure 2B;
F = 5.456, P = 0.009), and the CRH mRNA expression
was significantly increased in the hypothalami of the rats in
the nesfatin-1 (40µg/kg) group (Figure 2C) compared with
the controls. As shown in Figure 2C, there was no significant
difference in the mRNA expression of NUCB2/nesfatin-1 in the
hypothalami among the four groups (F = 2.504, P = 0.096).
Depression-like Behavior Induced by the
Chronic Administration of Nesfatin-1
The analysis of the bodyweight using a repeated measures
ANOVA showed that the training days (F = 102.706, P < 0.001),
but not exposure to nesfatin-1 (F = 0.048, P= 0.986) affected the
bodyweight, with an interactive effect (F = 4919.133, P < 0.001).
Figure 3 shows the changes in the behavior test results
induced by the chronic administration of nesfatin-1. In the
OFT (Figures 3A–D), the results showed that both the time and
nesfatin-1 treatment affected the total moving distance (time
effect: F = 17.513, P < 0.001; treatment effect: F = 6.060, P =
0.002; interaction effect: F = 283.130, P<0.001), the frequency
of rearing (time effect: F = 20.054, P<0.001; treatment effect:
F = 7.554, P < 0.001; interaction effect: F = 246.839, P <
0.001), and the frequency of grooming (time effect: F = 2.445,
P < 0.001; treatment effect: F = 4.031, P = 0.014; interaction
effect: F = 326.496, P < 0.001). A time effect was also found
for the duration in the center (time effect: F = 4.707, P =
0.015; treatment effect: F = 1.887, P = 0.149; interaction effect:
F = 11.405, P = 0.002).
In the sucrose preference test (Figure 3E), our results showed
that neither the time nor the nesfatin-1 treatment affected the
sucrose preference index (time effect: F = 0.393, P = 0.678;
treatment effect: F = 1.852, P = 0.155; interaction effect: F =
2958.698, P < 0.001).
In the FST, after the 3-weeks period of nesfatin-1
administration, the rats spent a longer time immobile and
less time struggling (Figure 3F).
Interestingly, the results of the Spearman correlation analysis
showed that the dose of nesfatin-1 administered was positively
correlated with the immobility in the FST (r = 0.589,
P<0.001) but negatively correlated with the frequencies of rearing
(r = −0.502, P = 0.001) and grooming (r = −0.450, P = 0.004)
in the last OFT.
Hyperactivity of the HPA Axis Induced by
the Chronic Administration of Nesfatin-1
As expected, the plasma CORT concentration (Figure 4A) and
hypothalamic expression of CRH mRNA (Figure 4B) were both
significantly increased after the 3-weeks period of nesfatin-1
administration (10, 20, 40µg/kg) (CORT: F = 4.741, P = 0.007;
CRH: F = 4.574, P = 0.014) Although the mRNA expression
of NUCB2/nesfatin-1 in the hypothalami (Figure 4B) was not
different among the four groups (F = 0.743, P = 0.539),
the chronic administration of nesfatin-1 (20µg/kg) markedly
increased the plasma concentration of nesfatin-1 (Figure 4A).
The results of the Spearman correlation analysis showed that
there was a dose-effect relationship between nesfatin-1 exposure
and the increase in the plasma CORT concentration (r = 0.559,
P < 0.001) and the hypothalamic expression of CRH mRNA
(r = 0.436, P = 0.033).
Increased mRNA Expression of
Synaptotagmin I and Synapsin I in the
Hypothalamus Induced by Chronic
Administration of Nesfatin-1
Figure 5 shows the mRNA expression of synaptotagmin I and
synapsin I in the hypothalami of the rats in the different groups.
After the 3-weeks of nesfatin-1 administration (20, 40µg/kg), the
hypothalamic mRNA expression levels of synaptotagmin I and
synapsin I were up-regulated compared with the control group
(synaptotagmin I: F = 9.590, P = 0.002; synapsin I: F = 6.742,
P = 0.006).
The results of the Spearman correlation analysis showed
the positive correlation between nesfatin-1 exposure and the
hypothalamic expression of synaptotagmin I mRNA (r = 0.910,
P<0.001) and synapsin I mRNA (r = 0.877, P < 0.001).
Increased Plasma Concentrations of IL-6
and CRP Induced by the Chronic
Administration of Nesfatin-1
Figure 6 shows the plasma concentrations of IL-6 and CRP in
all groups. The 3-weeks of nesfatin-1 administration remarkably
increased the plasma IL-6 (F = 21.775, P < 0.001) and CRP
(F = 20.569, P < 0.001) levels in a dose-dependent manner
(IL-6: r = 0.801, P < 0.001; CRP: r = 0.834, P < 0.001). The
results of the Pearson correlation analysis showed that the plasma
IL-6 and CRP concentrations were both positively correlated with
the immobility (IL-6: r = 0.329, P = 0.041; CRP: r = 0.362, P =
0.023) in the FST and the plasma CORT level (IL-6: r= 0.390, P =
0.016; CRP: r = 0.554, P < 0.001). The plasma concentration of
CRP, but not IL-6, was negatively correlated with the frequencies
of rearing (CRP: r = −0.359, P = 0.025; IL-6: r = −0.267,
P = 0.101) and grooming (CRP: r = −0.405, P = 0.011; IL-6:
r = −0.285, P = 0.079) in the last OFT.
Although, the sample size is limited, positive relationships
were also found between the plasma CRP and IL-6
concentrations and the hypothalamic mRNA expression of
synaptotagmin I (CRP: r = 0.646, P = 0.008; IL-6: r = 0.641,
P = 0.007) and synapsin I (CRP: r = 0.635, P = 0.008; IL-6: r =
0.629, P = 0.009).
DISCUSSION
In the present study, we first demonstrated that an intraperitoneal
administration of a single dose of nesfatin-1 increased the
immobility of rats in the FST and induced the hyperactivity
of the HPA axis. Based on these results, together with the fact
that chronic administration is a route delivery method in clinic,
we explored the effect of chronic nesfatin-1 treatment on the
depression-like behavior of rats and the underlying mechanism.
The results showed that after chronic nesfatin-1 administration,
the rats exhibited increased immobility in the FST, and decreased
activity and exploratory behavior in the OFT, which were
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FIGURE 3 | Effect of chronic nesfatin-1 administration on the performance of rats in the open field test (OFT), FST and sucrose preference test. The
data are presented as the mean ± SEM, with n = 10 for each group. In the OFT, both the time and nesfatin-1 treatment affected the total moving distance (A), the
number of rearing (C), and the number of grooming (D). A time effect was also found for the duration in the center (B). In the sucrose preference test, neither the time
nor the nesfatin-1 treatment affected the sucrose preference index (E). In the FST, after 3-we-eks period of nesfatin-1 administration, the rats spent a longer time
immobile and less time struggling (F). *P < 0.05 and **P < 0.001 compared with the control group.
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FIGURE 4 | Effect of chronic nesfatin-1 administration on the plasma
concentrations of CORT and nesfatin-1 and the hypothalamic mRNA
expression of CRH and nesfatin-1 in rats. The data are presented as the
mean ± SEM. Nesfatin-1 treated rats exhibited hyperactivity of the HPA axis,
as indicated by the elevated serum CORT concentration (A) (n = 10 for each
group) and the CRH mRNA expression in the hypothalamus (B) (n = 5 for
each group). Although the plasma nesfatin-1 concentration increased in the
nesfatin-1 (20µg/kg) group (A), the hypothalamic mRNA expression of
nesfatin-1 did not change after 3-weeks of consecutive administration of
nesfatin-1 (B). *P < 0.05 and **P < 0.001 compared with the control group.
accompanied by a hyperactive HPA axis, as indicated by the
increased levels of plasma CORT and hypothalamic CRHmRNA.
Increased mRNA expression levels of synaptotagmin I and
synapsin I in the hypothalami were also found in the nesfatin-1-
treated rats. Moreover, the chronic administration of nesfatin-1
elevated the plasma concentrations of CRP and IL-6, which were
correlated with the lower activity and despair behavior, the HPA
hyperactivity, and the changes in the expression of the synaptic
proteins.
The stress-associated activation of NUCB2/nesfatin-1
neurons, together with nesfatin-1’s central functions in the brain
indicated its potentially significant role in the stress adaptation
response. Results from human studies have provided more data
linking nesfatin-1 to the onset of depression (Ari et al., 2011;
Bloem et al., 2012). In the present study, our results showed that
FIGURE 5 | Effect of chronic nesfatin-1 administration on the
hypothalamic mRNA expression of synaptotagmin I and synapsin I in
rats. The data are presented as the mean ± SEM, with n = 5 for each group.
The hypothalamic mRNA expression levels of synaptotagmin I and synapsin I
in nesfatin-1 treated rats were up-regulated compared with those in the
controls. *P < 0.05 and **P < 0.001 compared with the control group.
the intraperitoneal administration of a single dose of nesfatin-1
and the chronic administration of nesfatin-1 increased the
immobility in the FST and that the chronic administration
of nesfatin-1 decreased the activity and exploratory behavior
of the rats in the OFT. Moreover, when given chronically,
nesfatin-1 was dose-dependently correlated with the despair-like
behavior. In stress-induced depression studies, lowered activity
and behavioral despair, as indicated by the reduced moving
distance and low levels of rearing and grooming in the OFT, and
increased immobility in the FST are often used as indices of a
depressive-like state (Izumi et al., 1997; Ge et al., 2013). Thus, the
present study emphasizes the important role of nesfatin-1 in the
stress-related response. We are not exactly sure about the reason
why the performance of the nesfatin-1-treated rats in FST were
similar after acute and chronic administration, although it may
be interpreted partly by the possibility that steady state plasma
concentration of nesfatin-1 reach when chronically treated.
However, we could not provide effective pharmacokinetic
parameters of nesfatin-1 to back up this hypothesis in the present
study.
Surprisingly, in the sucrose preference test, the sucrose
preference index was not significantly different between the
nesfatin-1-treated rats and the controls. However, our results
indicated that the rats in the nesfatin-1-treated group drank less
plain water, which was partly consistent with the results reported
by Yosten et al. that ICV nesfatin-1 significantly inhibited
the drinking response of rats, which was independent of its
anorexigenic effect (Yosten et al., 2012).
Hyperactivity of the HPA axis is thought to play an important
role in the etiology of depression (Swaab et al., 2005; Ge
et al., 2014). In the present study, our results showed that the
intraperitoneal administration of nesfatin-1 in a single dose or
chronically could induce the hyperactivity of the HPA axis, as
indicated by the increases in the plasma CORT concentration
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FIGURE 6 | Effect of chronic nesfatin-1 administration on the plasma
concentrations of IL-6 and CRP in rats. The data are presented as the
mean ± SEM, with n = 10 for each group. The plasma concentrations of IL-6
and CRP in the nesfatin-1-treated rats were higher than those in the control
rats. **P < 0.001 compared with the control group.
and the hypothalamic expression of CRH mRNA, which was
consistent with the effect of centrally administered nesfatin-
1 (Konczol et al., 2010; Yoshida et al., 2010). Moreover,
when nesfatin-1 was administered chronically, the results of
the Spearman correlation analysis demonstrated a dose-effect
relationship between nesfatin-1 exposure and the hyperactivity
of the HPA axis. These findings indicated that the effects of
nesfatin-1 were associated with the HPA axis.
Synaptic vesicle proteins have been identified as possible
factors involved in the pathophysiology of psychiatric disorders
including depression. Region specific changes in the expression
of synaptotagmin I and synapsin I have been reported to be
induced by both stress and antidepressant (Dagyte et al., 2011;
Müller et al., 2011), suggesting a regulatory role of synaptotagmin
I and synapsin I in the pathogenesis of depression. In the
present study, our results showed that the mRNA expression
levels of synaptotagmin I and synapsin I were increased in
the hypothalamus following nesfatin-1 treatment. Given the
findings that Ca2+ binding synaptotagmin I functions as a
calcium sensor in the regulation of neurotransmitter release and
that the primary role of synapsin I is the regulation of vesicle
turnover, it is predicted that changes in their expression will affect
synaptic plasticity. Our data thus, indicated that modulation
of synaptic function may be involved in the depression-
like behavior induced by nesfatin-1. Although the mechanism
remains unknown, it may be partly ascribed to the hyperactivity
of the HPA axis induced by nesfatin-1, based on the findings
that synapsin-Ia/Ib and synaptotagmin are the effectors of the
glucocorticoid-signaling cascade (Revest et al., 2010; Wuwongse
et al., 2013).
The multicausal etiology of depression may also be explained
by activated immune-inflammatory pathways (Maes et al.,
2014). IL-6, together with CRP, has received much attention
in the pathogenesis of depression (Liu et al., 2014; Wium-
Andersen et al., 2014). An increased IL-6 concentration has
been detected in depressed patients (Maes et al., 2001) and
animals (Voorhees et al., 2013), and the administration of IL-6
could produce depressive-like behaviors in mice (Sukoff Rizzo
et al., 2012). Moreover, it has been reported that increased IL-6
levels contributed to heightened HPA axis activity (Leonard
and Maes, 2012; Maes et al., 2014), and significant positive
correlation was found between the cortisol and CRP levels
(Cubala and Landowski, 2014). In the present study, the chronic
administration of nesfatin-1 increased the plasma concentrations
of IL-6 and CRP, which were positively correlated with the
despair behavior and the plasma CORT concentration. These
results indicated that IL-6 and CRP may play an important
role in the pathogenesis of nesfatin-1 induced depression-like
changes. Together with the results of the Pearson correlation
test, it is rational to hypothesize that the immune-inflammatory
activation is the central hub that linked the imbalance of synaptic
vesicle proteins and the depression-like behavior induced by
nesfatin-1administration.
Although the original function identified for nesfatin-1 was
its inhibition of dark cycle food intake (Mortazavi et al., 2015), it
has been reported that the peripheral infusion of nesfatin-1 has
no effect on dark or light cycle food intake or body weight (Li
et al., 2013). Consistent with this finding, there was no significant
difference in bodyweight between the nesfatin-1-treated rats and
the controls in the present study.
Conflicting results have also been reported regarding the
effects of nesfatin-1 on glucose metabolism and insulin secretion.
It has been demonstrated that the peripheral infusion of
nesfatin-1 could significantly affect glucose metabolism through
a direct peripheral mechanism to increase insulin secretion
and insulin sensitivity (Gonzalez et al., 2011; Li et al., 2013)
but both increased and decreased plasma levels of nesfatin-1
were reported in patients with newly diagnosed type 2 diabetes
mellitus (Li et al., 2010; Zhang et al., 2012). However, in the
present study, a consecutive 3-week intraperitoneal treatment
with nesfatin-1 did not affect the plasma concentrations of
glucose and insulin in rats (Supplementary Materials). This
discrepancy may be the result of differences in the study designs
and experimental conditions. In the case of lipid metabolism,
although the plasma concentrations of VLDL and TC increased
after the chronic administration of nesfatin-1 (40µg/kg), other
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lipid-associated indicators remained unchanged in the present
study (Supplementary Materials).
There are several limitations of this study that should be
noted. First, the design of the behavior tests was imperfect.
For example, the locomotor activity was only measured via the
OFT, and we did not test whether the behavior changes could
be reversed by treatment with an antidepressant. Therefore,
detailed investigations should be conducted in the future.
Second, the plasma and brain nesfatin-1 levels in the acute
experiment were not measured, which may help determine
whether nesfatin-1 crossed the brain-blood barrier to better
understand the mechanisms underlying the effects of nesfatin-
1 on behavior. Third, the parameters evaluated in the acute
treatment experiment were too limited to compare the difference
of the effect between a single dose and chronic administration.
Indeed, the acute nesfatin-1 treatment was only a preliminary
experiment to investigate the possible link between nesfatin-1
and depression. Based on the findings that nesfatin-1 given in a
single dose could increase the immobility in the force swimming
test, the CORT concentration, and the CRH expression, we
conducted the scheme of chronic administration of nesfatin-1.
In conclusion, our results demonstrated that the
intraperitoneal administration of nesfatin-1 in a single dose
or chronically resulted in despair behavior and HPA axis
hyperactivity. When given chronically, the depression-like
effect of nesfatin-1 is correlated with an increase in plasma
concentrations of IL-6 and CRP, which is accompanied by an
imbalance in the mRNA expression of synaptotagmin I and
synapsin I in the hypothalamus.
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